Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

NCT05320757 ↗

Phase 0 Completed 20 enrolled The University of Hong Kong

NaSingle-groupOpen-labelBasic science

Summary

This is a window study where treatment-naïve patients will receive olaparib before definitive treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP inhibitor.

Timeline

Start: 2022-04-01
Primary completion: 2025-05-31
Completion: 2025-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaparib	Small molecule	300 mg	Oral

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Summary

Timeline

Drugs

Indications